Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058006 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00058006: Completed Phase 2 study, sponsored by Northwestern University.
NCT00058006 is a Phase 2 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058006, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of stage I or stage II head and neck cancer or stage I non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to that of a placebo in preventing disease recurrence in patients with stage I or stage II head and neck cancer or stage I non-small cell lung cancer.
Interventions
- PROCEDURE adjuvant therapy
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00058006 record still lists
NCT00058006 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which adjuvant therapy is the first listed.
NCT00058006 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00058006 about?
NCT00058006 is a clinical study titled "Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of stage I or stage II head and neck cancer or stage I non-small cell lung cancer. PURPOSE: This randomize...
What is the current status of trial NCT00058006?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00058006?
The interventions under investigation include: adjuvant therapy (PROCEDURE), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00058006?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia